Continuing pursuit for ideal systemic anticancer radiotherapeutics. - Wikidata - awgldk - TriplyDB

Continuing pursuit for ideal systemic anticancer radiotherapeutics.

Continuing pursuit for ideal systemic anticancer radiotherapeutics.

http://www.wikidata.org/entity/Q37946750

about

Necrosis avid near infrared fluorescent cyanines for imaging cell death and their use to monitor therapeutic efficacy in mouse tumor models.Necrosis targeted combinational theragnostic approach using radioiodinated Sennidin A in rodent tumor models.Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models.Exploring theranostic potentials of radioiodinated hypericin in rodent necrosis models.Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications.The recent progress of the mechanism and regulation of tumor necrosis in colorectal cancer.Biodistribution and anti-tumor efficacy of intratumorally injected necrosis-avid theranostic agent radioiodinated hypericin in rodent tumor models.

P2860

Q30388052-F54EBFEF-B797-4026-85E2-8BF21C442974 Q33917524-9A1EA711-4284-4F66-8407-08000E8F911F Q35987317-58732636-2362-4CC3-AB1C-15D1D6EC0726 Q36383717-B2070911-4B44-4C94-8D0F-A1379844A1EF Q36609881-7A273BDF-0F9C-4EA7-A88C-BE417D79FFBC Q38533166-EE1DE371-F9E6-408C-BC71-1B827FC16725 Q38921976-7DB95B23-269E-410F-9FC8-A6FC93EFE42C

P2860

Continuing pursuit for ideal systemic anticancer radiotherapeutics.

http://www.wikidata.org/entity/Q37946750

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Continuing pursuit for ideal systemic anticancer radiotherapeutics.

@en

Continuing pursuit for ideal systemic anticancer radiotherapeutics.

@nl

type

label

Continuing pursuit for ideal systemic anticancer radiotherapeutics.

@en

Continuing pursuit for ideal systemic anticancer radiotherapeutics.

@nl

prefLabel

Continuing pursuit for ideal systemic anticancer radiotherapeutics.

@en

Continuing pursuit for ideal systemic anticancer radiotherapeutics.

@nl

P1433

Q37946750-59FFC27F-37F5-4E07-BD71-56FE14CBD8DE

P1476

Q37946750-A43D44EE-5B19-4461-8E90-F2A08F1F3A1E

P2093

Q37946750-05014128-652A-4B85-B490-72D66526A1DB

Q37946750-0A77F538-63E1-4035-93D9-68F66422B933

Q37946750-653FB5A8-F817-4CF3-9BC6-6E6925DB3017

Q37946750-A69693C2-76D6-4AB6-9E8E-339CB5206482

Q37946750-C8EC3F50-26EA-40E6-AB71-A45A70A851A5

Q37946750-CCC63E52-F13F-4ABC-9EF0-C07BC2335539

Q37946750-FA1F6C7B-B9E8-44EA-A577-F2B4D00B45DD

P2860

Q37946750-00709298-2E8D-421E-A064-20853A04738D

Q37946750-0582C49C-7150-4054-85FB-06E8221B83A3

Q37946750-062B2925-C019-4823-9790-A0F8FB9DDA75

Q37946750-1035B865-2236-4598-94DD-41E7120BC082

Q37946750-11011255-BAD9-4536-AC67-F9F270FE8857

Q37946750-1B51EF13-D6E8-4A59-905A-108AD505751F

Q37946750-1C4BE6BF-879A-4ECC-A255-81881D570E96

Q37946750-1CBCA638-D3F5-48DD-BD28-90D57BA73078

Q37946750-1DD59789-2151-43A8-8CFE-2D3F70EC5306

Q37946750-2063E7E9-7FF4-4C0C-8EC5-264C6D7C79E9

P2888

Q37946750-9AF6321B-BAA1-44F4-B482-0643596BB134

P304

Q37946750-247AA30E-DF67-4FB5-A3A6-0E7BCF0ECA03

P31

Q37946750-3771506C-1976-4A2F-84C0-F211AB365017

P356

Q37946750-AD79139A-5D8F-4314-A974-F1CF6DF781B0

P433

Q37946750-A53438DC-534D-48A0-B639-FE004B33C943

P478

Q37946750-9FE5AF34-28C4-4CBB-9B7F-94E5B3060C66

P50

Q37946750-DE0BB73F-1C90-4F8C-8F25-EA3A6AC31DC9

P577

Q37946750-C25DD2F5-3794-474B-B89D-2526675F196D

P5875

Q37946750-59C4FFB2-75B0-491E-B33B-77A7F8B4E07B

P698

Q37946750-741BAB96-B022-45F3-B49A-6D80D18D8965

P356

S10637-011-9758-6

P1433

Investigational New Drugs

P1476

Continuing pursuit for ideal systemic anticancer radiotherapeutics.

@en

P2093

Alfons Verbruggen

http://www.w3.org/2001/XMLSchema#string

Feng Chen

http://www.w3.org/2001/XMLSchema#string

Huaijun Wang

http://www.w3.org/2001/XMLSchema#string

Junjie Li

http://www.w3.org/2001/XMLSchema#string

Marlein Miranda Cona

http://www.w3.org/2001/XMLSchema#string

Yicheng Ni

http://www.w3.org/2001/XMLSchema#string

Yuanbo Feng

http://www.w3.org/2001/XMLSchema#string

P2860

Humanization of an anti-p185HER2 antibody for human cancer therapy

"Diabodies": small bivalent and bispecific antibody fragments

Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas

Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass

Continuous cultures of fused cells secreting antibody of predefined specificity

Amino acid sequence of the Fv region of a human monoclonal IgM (protein WEA) with antibody activity against 3,4-pyruvylated galactose in Klebsiella polysaccharides K30 and K33

Somatostatin and its receptor family

Improving the efficacy of antibody-based cancer therapies

Overview of monoclonal antibodies in cancer therapy: present and promise

Antibody-targeted radiation cancer therapy

P2888

s10637-011-9758-6

P304

2050-2065

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-011-9758-6

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51725812

http://www.w3.org/2001/XMLSchema#string

P698

22006160

http://www.w3.org/2001/XMLSchema#string